FDA Launches Accelerated Rare Disease Cures Program

News
Article

The agency’s Center for Drug Evaluation and Research has launched the new program to increase development of treatment options for patients with rare diseases.

FDA announced on May 10, 2022 that its Center for Drug Evaluation and Research (CDER) has launched a new program to increase and speed up the development of treatments for unmet needs of patients with rare diseases. The program, which will be managed by CDER’s Rare Diseases Team, will use CDER’s expertise to coordinate activities involved in the treatment of rare diseases.

According to FDA, development of treatments for rare diseases is complex, and using well-established trial designs and endpoint selection can be challenging because of the limited understanding of these conditions. The Accelerating Rare disease Cures (ARC) program will support the development and approval of these treatment options through scientific and regulatory engagement.

“CDER is optimistic about the future of rare disease drug development and is looking forward to continuing this important work under the new CDER ARC Program—together with patients, advocacy groups, academics, industry, and other partners—to address the significant unmet needs of patients and families living with rare diseases,” the agency stated in a press release.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes